NASDAQ:DYAI Dyadic International (DYAI) Stock Price, News & Analysis $1.20 -0.01 (-0.48%) Closing price 03:59 PM EasternExtended Trading$1.19 -0.01 (-0.77%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Dyadic International Stock (NASDAQ:DYAI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Dyadic International alerts:Sign Up Key Stats Today's Range$1.17▼$1.2450-Day Range$1.18▼$1.5052-Week Range$0.93▼$2.67Volume63,245 shsAverage Volume70,024 shsMarket Capitalization$36.09 millionP/E RatioN/ADividend YieldN/APrice Target$6.00Consensus RatingBuy Company OverviewDyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.Read More… Dyadic International Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks58th Percentile Overall ScoreDYAI MarketRank™: Dyadic International scored higher than 58% of companies evaluated by MarketBeat, and ranked 579th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingDyadic International has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageDyadic International has received no research coverage in the past 90 days.Read more about Dyadic International's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Dyadic International are expected to decrease in the coming year, from ($0.18) to ($0.19) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dyadic International is -5.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Dyadic International is -5.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDyadic International has a P/B Ratio of 6.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Dyadic International's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.56% of the float of Dyadic International has been sold short.Short Interest Ratio / Days to CoverDyadic International has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Dyadic International has recently decreased by 30.20%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDyadic International does not currently pay a dividend.Dividend GrowthDyadic International does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.56% of the float of Dyadic International has been sold short.Short Interest Ratio / Days to CoverDyadic International has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Dyadic International has recently decreased by 30.20%, indicating that investor sentiment is improving significantly. News and Social Media2.9 / 5News Sentiment1.22 News SentimentDyadic International has a news sentiment score of 1.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.83 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Dyadic International this week, compared to 1 article on an average week. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Dyadic International insiders have not sold or bought any company stock.Percentage Held by Insiders28.80% of the stock of Dyadic International is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 27.95% of the stock of Dyadic International is held by institutions.Read more about Dyadic International's insider trading history. Receive DYAI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dyadic International and its competitors with MarketBeat's FREE daily newsletter. Email Address DYAI Stock News HeadlinesDyadic International, Inc. to Announce First Quarter 2025 Financial Results and Host Conference Call on May 14, 2025May 1 at 4:04 PM | quiverquant.comDyadic to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025May 1 at 3:00 PM | globenewswire.comMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millions of years. And both grizzled oilmen and clean energy supporters love it: Energy Secretary Chris Wright called it "an awesome resource," while Warren Buffett, Jeff Bezos, Mark Zuckerberg, and Bill Gates are all directly invested.May 2, 2025 | Stansberry Research (Ad)Dyadic to Present at World Vaccine Congress | WashingtonApril 16, 2025 | globenewswire.comEarnings call transcript: Dyadic Q4 2024 shows revenue beat, EPS missMarch 28, 2025 | investing.comDyadic International, Inc. (NASDAQ:DYAI) Q4 2024 Earnings Call TranscriptMarch 28, 2025 | msn.comDYAI: CEPI Grants Recognize C1March 28, 2025 | msn.comQ4 2024 Dyadic International Inc Earnings CallMarch 27, 2025 | uk.finance.yahoo.comSee More Headlines DYAI Stock Analysis - Frequently Asked Questions How have DYAI shares performed this year? Dyadic International's stock was trading at $1.75 on January 1st, 2025. Since then, DYAI stock has decreased by 31.5% and is now trading at $1.1992. View the best growth stocks for 2025 here. How were Dyadic International's earnings last quarter? Dyadic International, Inc. (NASDAQ:DYAI) posted its quarterly earnings results on Wednesday, March, 26th. The biotechnology company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.04) by $0.01. The biotechnology company earned $0.82 million during the quarter, compared to analyst estimates of $1.60 million. Dyadic International had a negative net margin of 188.09% and a negative trailing twelve-month return on equity of 149.16%. Read the conference call transcript. Who are Dyadic International's major shareholders? Top institutional shareholders of Dyadic International include Chapin Davis Inc. (2.80%) and Callan Capital LLC (0.17%). View institutional ownership trends. How do I buy shares of Dyadic International? Shares of DYAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Dyadic International own? Based on aggregate information from My MarketBeat watchlists, some other companies that Dyadic International investors own include Pfizer (PFE), Enbridge (ENB), Meta Platforms (META), Silvercorp Metals (SVM), Endeavour Silver (EXK), Hecla Mining (HL) and Advanced Micro Devices (AMD). Company Calendar Last Earnings3/26/2025Today5/02/2025Next Earnings (Estimated)5/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DYAI CIK1213809 Webwww.dyadic.com Phone(561) 743-8333Fax561-743-8343Employees7Year FoundedN/APrice Target and Rating Average Stock Price Target$6.00 High Stock Price Target$6.00 Low Stock Price Target$6.00 Potential Upside/Downside+395.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,800,000.00 Net Margins-188.09% Pretax Margin-188.06% Return on Equity-149.16% Return on Assets-59.81% Debt Debt-to-Equity Ratio1.54 Current Ratio5.15 Quick Ratio5.15 Sales & Book Value Annual Sales$3.50 million Price / Sales10.42 Cash FlowN/A Price / Cash FlowN/A Book Value$0.20 per share Price / Book6.05Miscellaneous Outstanding Shares30,091,000Free Float21,067,000Market Cap$36.41 million OptionableOptionable Beta0.98 Social Links 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:DYAI) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dyadic International, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dyadic International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.